Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma
Willsmore Z, Booth L, Patel A, Di Meo A, Prassas I, Chauhan J, Wu Y, Fitzpartick A, Stoker K, Kapiris M, Biswas D, Perucha E, Whittaker S, Tsoka S, Diamandis E, Middleton G, Tull T, Papa S, Lacy K, Karagiannis S. Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma. Journal For ImmunoTherapy Of Cancer 2025, 13: e011682. PMID: 40449958, PMCID: PMC12142029, DOI: 10.1136/jitc-2025-011682.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsAnti-PD-1 therapyStage III/IV melanomaAnti-PD-1Memory B cellsB cellsCheckpoint inhibitorsHigher IgG4Development of immune-related adverse eventsResponse to anti-PD-1 therapyClass-switched memory B cellsClass-switched B cellsAccurate predictive biomarkersDN2 B cellsExtrafollicular B cell responseCheckpoint inhibitor treatmentB cell frequenciesB cell responsesIL-10+Response to therapyIgE serum levelsImmune response profileHumoral immune response profileSerum antibody isotypesAdvanced melanoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply